CNS Pharmaceuticals (NASDAQ:CNSP) Director Faith Charles Buys 7,100 Shares

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Director Faith Charles acquired 7,100 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The shares were bought at an average price of $4.79 per share, for a total transaction of $34,009.00. Following the completion of the acquisition, the director owned 7,100 shares of the company’s stock, valued at $34,009. This trade represents a ? increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

CNS Pharmaceuticals Stock Up 6.7%

Shares of NASDAQ:CNSP opened at $5.10 on Thursday. CNS Pharmaceuticals, Inc. has a 12 month low of $1.90 and a 12 month high of $15.73. The company’s fifty day simple moving average is $3.29 and its 200 day simple moving average is $4.84. The firm has a market cap of $4.13 million, a price-to-earnings ratio of -0.17 and a beta of 2.62.

CNS Pharmaceuticals (NASDAQ:CNSP) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($7.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($8.82) by $1.52.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of CNS Pharmaceuticals in a research note on Monday, April 20th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $20.00.

Institutional Investors Weigh In On CNS Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CNSP. Armistice Capital LLC acquired a new position in shares of CNS Pharmaceuticals during the 2nd quarter worth about $335,000. Ikarian Capital LLC acquired a new position in shares of CNS Pharmaceuticals during the 4th quarter worth about $241,000. Finally, Boothbay Fund Management LLC acquired a new position in shares of CNS Pharmaceuticals during the 4th quarter worth about $71,000. 14.02% of the stock is currently owned by institutional investors and hedge funds.

CNS Pharmaceuticals Company Profile

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.